Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.9Last Year’s EPS
-1.16Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: 40.98%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in regulatory and clinical advancements, particularly with AMT-130, and a strong financial position. However, the declines in revenue and immunosuppression-related adverse events were noted as challenges.Company Guidance
During the uniQure First Quarter 2025 Earnings Conference Call, CEO Matt Kapusta highlighted several key metrics and guidance for the year. The company is advancing its gene therapy pipeline with four clinical stage programs, notably AMT-130 for Huntington's disease, which is on track for a BLA submission. The FDA granted AMT-130 breakthrough therapy designation, and productive interactions with the FDA have occurred, with a detailed regulatory update expected later this quarter. In terms of financials, uniQure holds over $400 million in cash as of March 31, 2025, after a $80 million follow-on offering, providing the financial flexibility to support ongoing programs. The company reduced its cash burn rate through strategic divestitures and restructuring, and its operations are funded into the second half of 2027. Additionally, the Phase 1/2 trials for refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS are progressing, with initial data from Fabry expected in the second half of 2025.AMT-130 Regulatory Progress
AMT-130 received breakthrough therapy designation from the FDA in April and is on track for a planned BLA submission. The company has had multiple productive interactions with the FDA, focusing on preparing for this submission.
Pipeline Expansion
uniQure expanded its clinical pipeline with the initiation of three additional clinical studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS.
Strong Financial Position
uniQure has more than $400 million in cash as of March 31, 2025, providing financial flexibility to advance its pipeline, including the planned BLA submission and launch of AMT-130.
Reduced Expenses
Research and development expenses decreased to $36.1 million from $40.7 million year-over-year, and selling, general, and administrative expenses decreased to $10.9 million from $13.9 million in the same period in 2024.
QURE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
QURE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $12.25 | $12.79 | +4.41% |
Feb 27, 2025 | $11.67 | $12.07 | +3.43% |
Nov 05, 2024 | $5.56 | $6.06 | +8.99% |
Aug 01, 2024 | $7.66 | $7.48 | -2.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does uniQure N.V. (QURE) report earnings?
uniQure N.V. (QURE) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is uniQure N.V. (QURE) earnings time?
uniQure N.V. (QURE) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QURE EPS forecast?
QURE EPS forecast for the fiscal quarter 2025 (Q2) is -0.9.